Insider buying last 90 days
No open-market insider purchases were filed for QURE in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every QURE insider filing, plotted on the chart in Gekko.Open QURE in Gekko
NASDAQ: QURE
uniQure (QURE) Stock Analysis & Forecast
Oct 12 close
$21.84−0.75 (−3.3%)
Gekko Brief
AI summaryOct 12 closeuniQure's week centered on 48-month data for its Huntington's disease gene therapy, AMT-130 (ifezuntirgene inilparvovec), which showed continued slowing of disease progression and a manageable safety profile but a significantly smaller treatment benefit compared with the prior 36-month readout. The release was followed by a 37.3% share drop and a securities investigation announcement from a law firm on behalf of investors. Barclays reiterated a Hold rating with a $28 price target, while a separate technical service shifted its call on the stock from "Strong Sell" to "Sell Candidate."
The stock closed at $21.84, down 3.3% on the day, and sits below both its 50-day average of $41.11 and its 200-day average of $29.69, with the one-month return at -50.9% and the three-month return at -47.4%. The GekkoIndex reads 72.7, placing the stock in the Buying zone, down 8.4 over the past five sessions. Price stands 54.7% below the Gekko Fair Value of $48.16.
Over the next 20 trading days, the main event is the earnings date of 9 November 2026, 28 days away, before the open; the last report showed an EPS of -1.22 against an estimate of -0.81, with a 15.1% reaction, and prior reactions have averaged 16.4% in magnitude. No insider, Congress or unusual options activity appears in the current windows, though two Trailblazer holders are noted. Seasonality over five years shows a -1.7% average return across this 20-day stretch, with gains in 4 of those years. Consensus among 10 firms stands at 8 buy, 2 hold, 0 sell, with a target of $62.49.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
uniQure price vs fair value
Close $21.84200-day averageGekko Fair Value $48.16
uniQure quick facts
- Market cap
- $1.51B
- P/E ratio
- —
- Forward P/E
- 27.9
- EPS, TTM
- −$4.03
- Revenue, TTM
- $18.67M
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 1.06
- Volume
- 1.41M avg 3.42M
- 1-year return
- −65.7%
- Typical daily move
- ±14.2%
- Typical 20-day move
- ±12.7%
- 50-day average
- $41.11
- 200-day average
- $29.69
- Next earnings
- Nov 9 before open
- Shares outstanding
- 69.37M
uniQure swing-trade checklist
uniQure scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
- Trendmixed
Averages disagree
Close $21.84 sits between the 50-day ($41.11) and 200-day ($29.69) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
72.7, Buying
Reading 72.7 is in the Buying zone.
See the GekkoIndex - Fair valuesupportive
54.7% below
Price is 54.7% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 28 days
Reports on Nov 9, 2026, 28 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
−1.7% on average
From this point in the calendar, the next 20 trading days averaged −1.7% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
uniQure stock chart and price history
uniQure closed at $21.84 on Oct 12, 2026, −65.7% over the past year, inside a 52-week range of $8.73 to $71.50.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −50.9%
- 3 months
- −47.4%
- 6 months
- +21.9%
- 1 year
- −65.7%
The full QURE chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open QURE in Gekko
Follow uniQure through every session
Put QURE on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track QURE in GekkoFree for 7 days. No credit card required.
About uniQure
uniQure works on therapies for people facing rare and severe medical conditions in the United States. Its marketed product, HEMGENIX, helps those with hemophilia B produce factor IX, reducing bleeding risk. The company is also recognized for AMT-130, a gene therapy being studied in an early-stage clinical trial for Huntington's disease.
Beyond its approved treatment, uniQure is advancing several other gene therapy candidates still in early clinical testing, including ones aimed at mesial temporal lobe epilepsy, a form of ALS linked to the SOD1 enzyme, and Fabry disease. It carries out some of this work through outside partnerships, including a licensing arrangement with Apic Bio tied to its ALS-focused therapy and a supply and development agreement with CLS Behring.
The company traces back to 1998 and operates out of Amsterdam, in the Netherlands. uniQure is listed on the NASDAQ under the ticker QURE.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- uniqure.com
uniQure GekkoIndex: the smart money zone
uniQure’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 72.7, in the Buying zone, down 8.4 points over five sessions.
72.7Buying
Down 8.4 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying (current zone) | 55 | +36.7% | +53.7% |
| Accumulation | 227 | +2.8% | +15.7% |
| Neutral | 352 | +1.0% | +7.9% |
| Distribution | 38 | −4.8% | +36.9% |
| Selling | 10 | −0.1% | −0.1% |
Average QURE share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +3.1% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
See every daily GekkoIndex reading plotted over the QURE price, zone by zone.Track QURE in Gekko
Is uniQure stock overvalued? Gekko Fair Value
uniQure trades 54.7% below Gekko Fair Value of $48.16, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what uniQure shares are worth, recalculated every trading day.
$48.16
Gekko Fair Value, Oct 10, 2026
54.7% Undervalued
At the end of Aug 2026 the price was 20.0% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open QURE in Gekko
uniQure insider and Congress trading
No open-market insider purchases were filed for uniQure, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in QURE were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for QURE, plotted on the chart in Gekko.Open QURE in Gekko
Hedge funds and billionaires quarter ended Jun 30
2of the funds Gekko tracks hold QURE.
0added0opened2trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
uniQure earnings: next date and track record
uniQure reports on Nov 9, 2026, before the open (28 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 9, 2026
Expected before the open, 28 days away
- EPS estimate
- −$0.92
- Revenue estimate
- $6.21M
5 of 8reports beat the EPS estimate
±16.4%average move across the report
6 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 29, 2026 AI summary
- What they said
- uniQure's Q2 2026 earnings call focused on regulatory progress for AMT-130 in Huntington's disease, upcoming clinical data, commercial preparedness, and the company's financial position. Management reported alignment with the FDA that the 3-year Phase I/II data can serve as the primary basis for a BLA under the accelerated approval pathway, and that the FDA does not require a sham-controlled confirmatory trial; instead a randomized standard-of-care controlled confirmatory study with total functional capacity (TFC) at 36 months as the primary endpoint is expected. uniQure is on track for a third-quarter BLA submission and a contemporaneous MAA submission to the U.K. MHRA, and plans to disclose 4-year AMT-130 safety and tolerability data in September. The company strengthened its balance sheet via a follow-on offering and expects cash to fund operations into 2030. Clinical progress was also reported for Fabry disease and refractory temporal lobe epilepsy programs. During Q&A, management emphasized confidence in rapidly operationalizing and enrolling a global confirmatory trial, discussed endpoint choices and potential for an advisory committee, and reiterated commercial readiness activities focused on treatment center capacity, community engagement, and payer preparedness.
- Guidance
- On-track to submit a BLA for AMT-130 in Q3 2026 (accelerated approval pathway) and an MAA to the U.K. MHRA on a similar timeline; plan to disclose 4-year AMT-130 data in September 2026; intend to initiate the global confirmatory trial as soon as design alignment with FDA is reached; company expects cash runway/funding into 2030 to support the confirmatory trial, commercial launches and other trials. No numeric revenue or EPS guidance disclosed.
- Risks flagged
- Regulatory risks: potential FDA requests (e.g., Advisory Committee) and the need to finalize and execute a confirmatory trial design acceptable to regulators. Operational risks: the feasibility and timeline to fully enroll and complete the confirmatory trial, retention/dropout risk, and site/institutional logistical bottlenecks for a surgical administration. Commercial risks: payer access challenges, treatment center capacity constraints, and variability across healthcare systems. Clinical risks: uncertainty in final 4-year data and how it will be viewed in review or by an AdCom.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 29, 2026 | −$1.22 est −$0.81 | $5.84M est $5.45M | +15.1% |
| May 5, 2026 | −$0.73 est −$0.75 | — | +10.3% |
| Mar 2, 2026 | −$0.56 est −$0.93 | $5.57M est $5.33M | −42.2% |
| Nov 10, 2025 | −$1.38 est −$0.85 | $3.70M est $4.84M | +11.0% |
| Jul 29, 2025 | −$0.60 est −$0.76 | $5.26M est $4.63M | −3.5% |
| May 9, 2025 | −$0.73 est −$0.93 | $1.57M est $5.90M | +7.3% |
| Feb 27, 2025 | −$1.44 est −$0.52 | $5.22M est $18.45M | +12.7% |
| Nov 5, 2024 | −$0.91 est −$1.02 | $2.29M est $18.33M | +28.8% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
uniQure stock forecast and analyst price targets
Analysts’ average 12-month price target for uniQure is $62.49, +186.1% from the last close, from 10 firms rating the stock in the last 90 days.
$62.49consensus 12-month target, +186.1% from the last close
Now $21.84Avg $62.49
Low $28High $80
Each firm’s latest rating in the last 90 days: 10 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 5 | Barclays | $28 | +28.2% |
| Oct 2 | RBC Capital | $48 | +119.8% |
| Sep 30 | Goldman Sachs | $31 | +41.9% |
| Sep 30 | Barclays | $60 | +174.7% |
| Sep 30 | H.C. Wainwright | $80 | +266.3% |
+53.7%average 20-day move after past Buying readings
−1.7%average move over the next 20 trading days in the last 5 years
±14.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
uniQure seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, uniQure averaged −1.7% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.3% | 2 of 5 |
| Next 10 trading days | 0.0% | 1 of 5 |
| Next 15 trading days | +2.0% | 4 of 5 |
| Next 20 trading days | −1.7% | 4 of 5 |
| Next 30 trading days | −9.0% | 2 of 5 |
For scale, QURE’s typical 20-trading-day move in either direction is about 12.7%.
uniQure market cap and key statistics
uniQure’s market cap is $1.51B and revenue of $18.67M over the last twelve months.
Valuation
- Market cap
- $1.51B
- Forward P/E
- 27.9
- EPS, TTM
- −$4.03
- Gekko Fair Value
- $48.16
Trading
- Volume
- 1.41M
- Avg volume, 20 days
- 3.42M
- 52-week high
- $71.50
- 52-week low
- $8.73
- Shares outstanding
- 69.37M
Financials
- Revenue, TTM
- $18.67M
- Profit margin
- 0%
- Return on equity
- -157.6%
- Quarterly earnings growth, YoY
- −18.2%
Risk and income
- Beta
- 1.06
- Typical daily move
- ±14.2%
- Typical 20-day move
- ±12.7%
uniQure stock news this week
Coverage of uniQure this week reads negative: 1 positive, 1 neutral and 7 negative headlines.
- Uniqure N.v Stock Price Forecast. Should You Buy QURE?StockInvest.us, Oct 10
- uniQure N.V. (QURE) interactive stock chart – Yahoo FinanceYahoo Finance Singapore, Oct 8
- uniQure (NASDAQ:QURE) and Vir Biotechnology (NASDAQ:VIR) Critical ReviewDefense World, Oct 8
- uniQure N.V. (QURE) latest stock news and headlinesYahoo Finance Australia, Oct 7
- uniQure N.V. (QURE) Interactive Stock ChartYahoo! Finance Canada, Oct 7
- Barclays Maintains UniQure NV(QURE.US) With Hold Rating, Maintains Target Price $28富途牛牛, Oct 7
uniQure peers
uniQure’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
uniQure stock FAQ
What is uniQure’s market cap?
uniQure’s market cap is $1.51B at the Oct 12, 2026 close of $21.84, with 69.37M shares outstanding.
What is the uniQure stock forecast?
The consensus analyst 12-month price target for uniQure is $62.49, +186.1% from the last close. Of the 10 firms that rated the stock in the last 90 days, 8 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is uniQure stock overvalued or undervalued?
On Gekko’s estimate uniQure is undervalued: the Oct 12, 2026 close of $21.84 is 54.7% below Gekko Fair Value of $48.16. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does uniQure report earnings next?
uniQure is expected to report on Nov 9, 2026, before the market opens (28 days away). Analysts expect earnings of −$0.92 per share on revenue of $6.21M. uniQure beat the earnings estimate in 5 of its last 8 reports, moving 16.4% on average across the report.
What is uniQure’s 52-week high and low?
uniQure’s 52-week high is $71.50 and its 52-week low is $8.73; it closed at $21.84 on Oct 12, 2026, −65.7% over the past year.
Is uniQure stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (gekkoindex and fair value), 2 as mixed (trend and seasonality) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See uniQure the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.